Gold prices edge higher; Fed indepedence fears spur safe haven buying
Director Melinda Brown of Precision Biosciences INC (NASDAQ:DTIL) recently purchased 1,682 shares of common stock, according to a Form 4 filing with the Securities and Exchange Commission. The shares were bought at prices ranging from $4.14 to $4.15, with the total transaction amounting to $6963. The purchase comes as the stock has fallen nearly 14% over the past week, though InvestingPro analysis suggests the stock is currently undervalued.
The transaction, which occurred on June 25, 2025, resulted in Brown directly owning 20,565 shares of Precision Biosciences INC. The company, with a market capitalization of $46 million, maintains a strong liquidity position with a current ratio of 6.62 and more cash than debt on its balance sheet. InvestingPro subscribers can access 8 additional key insights about DTIL’s financial health and future prospects.
In other recent news, Precision BioSciences announced that its gene editing therapy PBGENE-DMD for Duchenne muscular dystrophy has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. This designation could make the company eligible for a Priority Review Voucher upon potential FDA approval, which can expedite the review process for another product or be sold. The therapy uses Precision’s ARCUS platform and aims to benefit up to 60% of DMD patients by enabling production of near full-length dystrophin protein. In another development, Precision BioSciences’ PBGENE-HBV therapy for chronic hepatitis B received Fast Track designation from the FDA. This designation aims to speed up the development and review of treatments for serious conditions, highlighting the potential of PBGENE-HBV to improve treatment options for chronic hepatitis B. The company is conducting a global Phase 1 trial for this therapy, with updates expected throughout 2025. Additionally, at Precision BioSciences’ recent annual shareholder meeting, Kevin J. Buehler and Shari Lisa Piré were elected as Class III directors. Shareholders also ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.